Literature DB >> 921594

Management of epistaxis in hereditary hemorrhagic telangiectasia. Review of 80 cases.

T V McCaffrey, E B Kern, C F Lake.   

Abstract

Intranasal dermoplasty and estrogen therapy have been shown to be the most effective means of managing epistaxis in patients with hereditary hemorrhagic telangiectasia. In a series of 80 patients studied, the most effective treatment was by intranasal dermoplasty; of 22 patients so treated, 14 had improvement for more than six months after surgery and six had improvement for one to six months. Regrafting for recurrent epistaxis was successful in four of five patients (improvement for more than six months). Estrogen was administered for systemic effect to 16 patients and produced improvement of more than six months' duration in eight and of one to six months' duration in three. Other forms of management were less effective for the prolonged control of epistaxis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 921594     DOI: 10.1001/archotol.1977.00780280027001

Source DB:  PubMed          Journal:  Arch Otolaryngol        ISSN: 0003-9977


  4 in total

1.  First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT).

Authors:  Basel Al Kadah; George Papaspyrou; Mathias Schneider; Bernhard Schick
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-23       Impact factor: 2.503

2.  A patient with polycythemia.

Authors:  J E Olerud; H T Robertson; K F Hossack; W B Nelp; G F Odland; W D Bowman; C A Finch
Journal:  West J Med       Date:  1981-11

3.  Pial arteriovenous fistula in children as presenting manifestation of Rendu-Osler-Weber disease.

Authors:  R García-Mónaco; W Taylor; G Rodesch; H Alvarez; P Burrows; P Coubes; P Lasjaunias
Journal:  Neuroradiology       Date:  1995-01       Impact factor: 2.804

4.  Oestrogen deficiency and bleeding from large bowel telangiectasia in Turner's syndrome.

Authors:  J P O'Hare; M Hamilton; J D Davies; R J Corrall; R Mountford
Journal:  J R Soc Med       Date:  1986-12       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.